Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
Saved in:
| Title: | Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. |
|---|---|
| Authors: | Cohen SB (AUTHOR), Emery P (AUTHOR), Greenwald MW (AUTHOR), Dougados M (AUTHOR), Furie RA (AUTHOR), Genovese MC (AUTHOR), Keystone EC (AUTHOR), Loveless JE (AUTHOR), Burmester G (AUTHOR), Cravets MW (AUTHOR), Hessey EW (AUTHOR), Shaw T (AUTHOR), Totoritis MC (AUTHOR), REFLEX Trial Group (CORPORATE AUTHOR) |
| Source: | Arthritis & Rheumatism. Sep2006, Vol. 54 Issue 9, p2793-2806. 14p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
